Abstract
Understanding strategic commitments and policy responses to overcome antimicrobial resistance at the national, regional, and global levels is required to evaluate current progress and direct future planning. National action plans (NAPs) are the primary mechanism for guiding national strategy and action for antimicrobial resistance governance. Although several NAPs have been developed, no comprehensive content analysis of these plans exists. Using a governance framework, we aimed to assess all publicly available NAPs on antimicrobial resistance.
Generated Summary
This study presents a systematic governance analysis of 114 countries’ national action plans (NAPs) on antimicrobial resistance (AMR) between 2020 and 2021. Using a governance framework, the research team assessed the NAPs based on three main areas: policy design, implementation tools, and monitoring and evaluation. The study aimed to evaluate current progress and guide future planning in addressing AMR at national, regional, and global levels. The research employed a mixed-methods approach, combining systematic literature searches, data extraction, and quantitative analyses. The study included the identification of 306 NAPs and content analysis of 114 publicly available NAPs. Data sources included the Tripartite Antimicrobial Resistance Country Self-Assessment Survey (TrACSS), the Global Antimicrobial Resistance and Use Surveillance System (GLASS), and others. The researchers developed criteria to standardize the process of quantifying each indicator and generated composite scores for governance areas. The data were transformed to a scale of 0 to 100 to rank countries and analyze trends. The research team used Google Neural Machine Translation software to convert contents of the NAPs in 41 native languages to English. The primary goal was to evaluate and assess the strategic responses to antimicrobial resistance and determine whether the global response is commensurate with the scale and severity of AMR.
Key Findings & Statistics
- The mean antimicrobial resistance governance score between 2020 and 2021 was 51 (SD 14).
- Norway had the highest governance score (mean 85 [SD 32]), and the Federated States of Micronesia had the lowest (28 [37]).
- The highest scoring domain was participation (83 [16]), while the lowest scoring domains were accountability (30 [18]) and feedback mechanism (30 [25]).
- Domains relating to policy design (55 [13]) and implementation tools (54 [17]) scored similarly.
- Monitoring and evaluation efforts were lower (38 [20]).
- A composite score for financing, not part of the framework, scored 30 (SD 16) across all countries.
- Of the 306 NAPs identified, 114 were eligible for analysis.
- The research team reviewed 114 NAPs and analyzed indicators for 114 countries, which provided 6156 scores on the basis of 15732 input datapoints in the TrACSS between 2020 and 2021.
- Overall country governance scores of antimicrobial resistance NAPs ranged from 85 (SD 32) in Norway to 28 (37) in Federated States of Micronesia.
- The domains with the lowest mean scores of 30 were accountability (SD 18) and feedback mechanism (SD 25), followed by education, which scored 32 (SD 16).
- Education was the lowest scoring domain of all implementation tools.
- Of the 20 countries with the highest overall governance scores, 17 were high-income countries, and 11 were from the European region.
- Most of the lowest-scoring 20 countries were upper-middle-income countries (n=8) and lower-middle-income countries (n=7); seven were island countries.
- The European region had the highest overall governance score (57 [SD 15]), and the Eastern Mediterranean region had the lowest (46 [8]).
Other Important Findings
- The study revealed substantial variability in the strategic responses to antimicrobial resistance among the 114 countries.
- The need to improve relevant governance and policy responses in all locations was highlighted.
- The international response, including efforts to monitor and evaluate interventions, might not be commensurate with the scale and severity of antimicrobial resistance.
- The study indicated that current policies might not be proportional to the magnitude of antimicrobial resistance, particularly in low-income and middle-income countries.
- Differences were found in the equity domain, which assessed whether NAPs encouraged responsible use of antimicrobials and facilitated access to antimicrobials.
- The study found that simply developing an NAP might not necessarily make a country prepared to respond to the threat of antimicrobial resistance.
- Most of the lowest-scoring 20 countries were upper-middle-income countries (n=8) and lower-middle-income countries (n=7); seven were island countries.
- Substantial differences were found in the equity domain, which assessed whether NAPs encouraged responsible use of antimicrobials and facilitated access to antimicrobials. High scores were found in the African region (55 [SD 35]), low-income countries (48 [38]), and lower-middle-income countries (54 [38]).
- The European region scored highest on surveillance (74 [24]), which could be indicative of more well-established laboratory capacity and higher-quality data collection systems compared with the African (43 [19]) and Eastern Mediterranean (42 [20]) regions.
- Sustainability indicator PD6.3, which considered whether countries had assessed future budget requirements for different activities listed in the NAPs, was the lowest scoring (1 [SD 9]), with only Austria scoring positively.
- The accountability indicator PD4.3, about whether agreements existed regarding repercussions if objectives were not met, scored 4 (18). Only four NAPs mentioned a formal follow-up review.
Limitations Noted in the Document
- The study’s reliance on self-assessment surveys (TrACSS) to generate scores for some indicators might have led to self-response bias.
- Validating each of the 5358 data points would be resource-intensive.
- Publicly accessible documents relevant to the study might not have been included due to omissions, and this could have inadvertently led to omissions.
- NAPs were retrievable from at least seven countries and territories that were not included in this analysis, as their absence from TrACSS 2020-21 prevented inclusion.
- Some composite scores consisted of varying numbers of constituent variables, which might have led to unintended weighting.
Conclusion
The study’s findings underscore the need for countries to enhance their strategic policy design, implementation tools, and monitoring and evaluation efforts in addressing antimicrobial resistance. The variation in governance scores across countries highlights the need for tailored approaches and the importance of learning from both successes and failures. The low scores in domains like accountability and feedback mechanisms point to critical areas needing improvement. The study’s insights suggest that a well-considered and costed NAP is crucial but may not be enough to effectively combat AMR. The focus on improving transparency and accountability, as well as addressing the inequities in access to medicines, is essential. The findings reinforce that the global response requires a concerted effort across multiple sectors, with a particular emphasis on robust monitoring, evaluation, and sustainable financing. Addressing the deficiencies identified in the study is paramount to improve accountability and ensure that the objectives set in the NAPs are met. The development of antimicrobial resistance governance requires continual improvement and adjustment, with a focus on strengthening implementation and evaluation of NAP activities. The authors emphasize the importance of promoting open access to crucial information and establishing formal follow-up reviews to enhance transparency and accountability. The global response to AMR benefits from these improvements and highlights the importance of a well-considered, well-costed NAP for addressing the complexities of AMR. The study also highlighted the importance of equity and the need to promote responsible use of antimicrobials, particularly in lower-middle-income countries. The assertion that the global response to antimicrobial resistance is favorable because of the development of as many as 148 NAPs is ill-conceived and inappropriate. The role of the NAP could be argued to be relatively inconsequential, as tangible action after the implementation of a plan establishes the most meaningful effects. We believe a well considered, well costed NAP with multisectoral relevance provides an important basis to direct priority setting and policy making.